On June 26, 2022, the FDA approved Merck’s Vaxneuvance™ for patients ages 6 weeks through 17 years old in addition to the previously approved age group of 18 years and older. Vaxneuvance™ is a pneumococcal vaccine that helps to protect against invasive pneumococcal disease (IPD) such as bacteremia, which is an infection in blood, and meningitis, which is an infection in the fluid and protective tissue surrounding the brain and spinal cord. The vaccine provides protection for 15 different types of pneumococcus bacteria, 3 of which are in the top 5 strains associated with childhood IPD. The approval was granted after evaluating the safety and efficacy data from 7 randomized, double-blind clinical trials in pediatric patients. Results showed that Vaxneuvance™ provides overall comparable protection in pediatrics with current pneumococcal vaccine, PCV13, and better protection in some types of pneumococcus bacteria. Some common side effects may include injection site reaction, irritability, headache and muscle aches. Vaxneuvance™ is a 4-dose series vaccine for pediatric patients. The series should be given at 2 months old, 4 months old, 6 months old and last injection given at 12 through 15 months old. It can also be given as a single dose in children over 2 years old who did not complete a series with another pneumococcal vaccine. Vaxneuvance™ should not be used in patients who have or have had a severe allergic reaction to any ingredients of the vaccine or to diphtheria toxoid. The CDC’s Advisory Committee on Immunization Practices will soon make recommendations on the use of the vaccine in pediatrics.